

INSTITUTIONAL RESEARCH Biotechnology UPDATE REPORT

Member FINRA/SIPC

Toll-Free: 866-928-0928 • www.DawsonJames.com • 101 North Federal Highway - Suite 600 • Boca Raton, FL 33432

Can-Fite BioPharma Ltd. (NYSE/CANF)

BUY: Namodenoson: Liver Cancer at ASCO Japan

Can-Fite's novel approach for the treatment of advanced liver cancer is set to be presented at the American Society of Clinical Oncology (ASCO) Breakthrough Meeting in Japan on August 4th, 2023. "A novel approach for the treatment of advanced hepatocellular carcinoma (HCC)" is one of the highest scoring abstracts and has won the prestigious Breakthrough Abstract Award from Conquer Cancer®, the ASCO Foundation, and the 2023 ASCO Breakthrough Program Committee.

Investment Highlights: Namodenoson

Namodenoson Pivotal Phase 3 Liver Cancer Study—Can-Fite's ongoing pivotal Phase 3 liver cancer study is designed to assess Namodenoson in the treatment of patients with advanced hepatocellular carcinoma (HCC) and underlying Child Pugh B7 (CPB7) who have not responded to 1 or 2 other lines of therapy. The primary endpoint is overall survival. An interim analysis will be performed.

A Phase 2a Pancreatic Cancer Study—Can-Fite is preparing for an open-label Phase 2 exploratory trial to assess the safety and efficacy of Namodenoson in the treatment of patients with pancreatic cancer who have received at least one previous systemic therapy.

A Phase 2b NASH Study—A Phase 2b NASH study is currently ongoing to evaluate Namodenoson's efficacy as compared to placebo, determined by a histological endpoint. Namodenoson met its primary endpoint of reducing liver fat, inhibiting fibrosis, and demonstrating an anti-inflammatory effect in a prior Phase 2a NASH study.

Background: Namodenoson has been evaluated in Phase 2 trials for two indications, as a second line treatment for hepatocellular carcinoma (HCC), and as a treatment for nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). It is currently in a Phase 2b trial for NASH, a pivotal Phase 3 for HCC, and is headed into a Phase 2a for pancreatic cancer. Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR). A3AR is highly expressed in diseased cells whereas low expression is found in normal cells. This differential effect accounts for the excellent safety profile of the drug.

Valuation. We evaluate Piclidenoson in Psoriasis, Namodenoson in HCC, and NAFLD, we do not include pancreatic cancer (yet). We apply a probability of success factor in these patient-based models. These metrics then flow into our valuation models. For Can-Fite, we use a 30% discount rate (in addition to the risk rate), as Can-Fite is not yet profitable, and most of the products are still dependent on the outcome of the clinical trials. Our valuation conclusion is an equally weighted average of our FCFF, EPS, and sum-of-the-parts analysis. We use a projected fully diluted end-year share count and assume multiple raises which results in our model.

Risks to our thesis include the following: (1) commercial; (2) regulatory; (3) clinical; (4) manufacturing; (5) financial; (6) liability; and (7) intellectual property.

July 18, 2023 Jason Kolbert Managing Director & Senior Analyst jkolbert@dawsonjames.com



Source: Can-Fite		
Stock Data		
52-Week Range	\$1.52 -	\$10.00
Shares Outstanding (mil.)		4.1
Market Capitalization (mil.)		\$12.7
Enterprise Value (mil.)		\$0.3
Debt to Capital		0.0%
Book Value/Share		\$45.18
Price/Book		3.7
Average Three Months Tradi	0.1	
Insider Ownership		-
Institutional Ownership		9.4%
Short interest (mil.)		0.9%
Dividend / Yield		\$0.00/0.0%






Exhibit 1. Income Statement

Can-Fite Biopharma.: Income Statement (\$000)																	
: YE December 31		2019A	2020A	2021A	2022A	1Q23A	2Q23E	3Q23E	4Q23E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E
evenue:		2,032	763	853	810												
Piclidenoson (CF-101), Rheumatoid Arthritis U.S.		_,			-	-	-	-	-	-	-	-	-	-	-	-	-
Piclidenoson (CF-101), Rheumatoid Arthritis EU					-	-	-	-	-	-	-	-	-	-	-	-	-
Piclidenoson (CF-101), Psoriasis U.S.														53,044	110,375	172,251	238,9
Piclidenoson (CF-101), Psoriasis EU														51,199	106,536	166,260	230,6
lamodenoson HCC U.S.												8,261	17,189	26,825	37,212	48,394	60,4
lamodenoson HCC EU							_	_	-		_	11,543	24,019	37,484	51,998	67,624	84,4
amodenoson NASH/NAFLD U.S.					-	-	-	-	-	-	-	11,545	24,013	57,404	51,550	07,024	04,4
lamodenoson NASH/NAFLD EU					-	-	-	-	-	-	-	-	-	-	-	-	
		2.032	700	050	-	-	-	-	-	-	-	-	-	-	306.121	454.529	011
otal Product Sales		2,032	763	853	810	-	-	-	-	-	-	19,804	41,208	168,553	306,121	454,529	614,4
lilestone From Gebro Holdings																	
iclidenoson (CF-101), Rheumatoid Arthritis U.S.																	
oyalty Rate from Global Partnership																	
iclidenoson (CF-101), Rheumatoid Arthritis EU																	
oyalty Rate from Global Partnership											_				_		
iclidenoson (CF-101), Psoriasis U.S.											-	-		13,261	27,594	43,063	59,7
oyalty Rate from Global Partnership											_			26%	26%	26%	2
iclidenoson (CF-101), Psoriasis EU											-	-		13,261	27,594	43,063	59,
oyalty Rate from Global Partnership														26%	26%	26%	
lamodenoson HCC U.S.											-	2,065	4,297	6,706	9,303	12,099	15,
oyalty Rate from Global Partnership												25%	25%	25%	25%	25%	
amodenoson HCC EU											-	2,886	6,485	10,121	14,040	18,258	22,
oyalty Rate from Global Partnership												25%	27%	27%	27%	27%	
amodenoson NASH/NAFLD U.S.											· .		-				
oyalty Rate from Global Partnership																	
lamodenoson NASH/NAFLD EU											· .					·	
Royalty Rate from Global Partnership					-					-	-	-	-	-	-	-	
Total royalties, collaborative revenue																	
Total Revenue		2.032	763	853	810	196				196	/	4,951	10,782	43,349	78,530	116,482	157,3
otal Revenue		2,032	703	600	810	190	-	-	-	190	-	4,951	10,762	43,349	78,330	110,402	157,5
xpenses:																	
artnership Costs including COGS		-	-	-	-		-	-	-	-	-	990	2,060	8,428	15,306	22,726	30,
	%COGS				0%	5%	5%	5%	5%	5%	5%	5%	5%	5%	5%	5%	00,
esearch and Development	/00000	10,976	11,951	9,850	7,763	2,061	1,900	2,059	2,138	7,918	8,077	8,238	8,403	8,571	8,742	8,917	9,0
research and Development	%R&D	10,970	11,951	9,000	7,703	2,001	1,900	2,039	2,130	7,910	8,077	0,230	0,403	0,571	0,742	0,917	9,0
Deneral and Administration	76ΚαD	2.050	2.054	2.045	2 4 4 2	0.47	2 000	2 4 2 0	2.240	12 000	12 600	12 220	12 002	14500	15 015	10 001	10.0
General and Administrative		3,059	2,951	3,845	3,143	847	2,880	3,120	3,240	12,000	12,600	13,230	13,892	14,586	15,315	16,081	16,8
	%SG&A																
otal Expenses		14,035	14,902	13,695	10,906	2,908	4,780	5,179	5,378	19,918	20,677	22,458	24,355	31,585	39,364	47,725	56,7
perating Income (Loss)		(12,003)	(14,139)	(12,842)	(10,096)	(2,712)	(4,780)	(5,179)	(5,378)	(19,722)	(20,677)	(17,507)	(13,572)	11,765	39,166	68,758	100,0
nance expenses		693	(,,	(,=)	(,)	(=,: :=)	(.,)	(=,=)	(0,010)	(,	(,,	(,)	(,)	,			,
inance income		3,109	(304)	227	(77)	162											
		0,100	(004)	227	(11)	102											
otal Other Income		2,416	(304)	227	(77)	162	-	-	-	· .	• _	· .	·	· .	· .	r .	
retax Income		(9,587)	(13.835)	(12,615)	(10,173)	(2.550)	(4.780)	(5,179)	(5,378)	(19,722)	(20,677)	(17,507)	(13,572)	11,765	39,166	68,758	100.6
axes on income		(3,301)	(10,000)	(12,010)	(10,170)	(2,000)	(4,700)	(0,173)	(0,010)	(13,722)	(20,011)	(17,507)	(10,012)	11,700	00,100	00,700	100,0
			(745)	(0.500)							(1.00.4)	(1.101)	-	500	0.017	44.004	05.
axes			(715)	(2,590)							(1,034)	(1,401)	-	588	3,917	11,001	25,
emeasurement loss from defined benefit plans																	
axRate											0%	0%	0%	5%	10%	16%	1
AAP Net Income (Loss)		(9,587)	(14,443)	(12,615)	(10,173)	(2,550)	(4,780)	(5,179)	(5,378)	(19,722)	(20,677)	(17,507)	(13,572)	11,176	35,250	57,756	75,
			(1.0-2)	(0.53)	(0.00)	(0.01)	10.10	(0.40)	10.17	(1.07)	//		(0.70)	0.01	0.00	0.07	
AAP-EPS		(1.77)	(1.02)	(0.58)	(0.28)	(0.31)	(0.42)	(0.46)	(0.47)	(1.87)	(1.30)	(1.00)	(0.78)	0.64	2.00	3.26	4
AAP-EPS (Dil)		(1.35)	(0.48)	(0.33)	(0.13)	(0.43)	(0.40)	(0.43)	(0.45)	(1.88)	(1.15)	(0.87)	(0.67)	0.55	1.73	2.83	3
- ()																	17,7
/gtd Avg ADR Shrs (Bas) - '000s		5,833	17,191 29,866	21,416	37,202	8,298	11,306	11,317	11,329 12,030	10,562	15,862 18,026	17,430 20,090	17,499	17,570 20,251	17,640 20,333	17,711	20,4

Source: Dawson James Securities estimates, company reports



Risk Analysis

In addition to the typical risks associated with development-stage specialty pharmaceutical companies, potential risks specific to Can-Fite are as follows:

Financial risk. The Company may need to raise capital in the marketplace, and there can be no assurances that the Company will be able to successfully raise capital and/or do so on favorable terms.

Clinical and regulatory risk. Lead products must start and complete clinical trials. Trials may not produce results sufficient for regulatory approval.


Partnership risk. Can-Fite may seek partnerships for clinical development support and commercialization. We have no specific knowledge of any discussions with possible partners today, and there can be no assurances that the Company will be able to secure a favorable partnership.

Commercial risk. There are no assurances that the Company will be able to secure favorable pricing, commercially launch products, and achieve significant market share to become profitable.

Legal and intellectual property risk. The Company may have to defend its patents and technical know-how, and there can be no assurances that the patents will not be infringed or will be held as valid if challenged, and or that the Company may infringe on third parties' patents.

Important Disclosures:

Price Chart:



Price target and rating changes over the past three years:

Update – Buy – March 5, 2020 – Price Target \$9 Update – Buy – April 13, 2020 – Price Target \$9 Update – Buy – April 20, 2020 – Price Target \$9 Update – Buy – May 19, 2020 – Price Target \$9 Update – Buy – June 1, 2020 – Price Target \$9 Update – Buy – June 9, 2020 – Price Target \$9 PT Change – Buy – June 10, 2020 – Price Target lowered from \$9 to \$7.0 Update – Buy – June 30, 2020 – Price Target \$7 Update – Buy – June 30, 2020 – Price Target \$7 Update – Buy – July 30, 2020 – Price Target \$7 Update – Buy – August 31, 2020 – Price Target \$7 PT Change – Buy – October 6, 2020 – Price Target \$5 Update – Buy – November 16, 2020 – Price Target \$5 Update – Buy – December 1, 2020 – Price Target \$5 Update – Buy – January 25, 2021 – Price Target \$5





Update - Buy - February 23, 2021 - Price Target \$5 Update - Buy - March 5, 2021 - Price Target \$5 Update - Buy - March 29, 2021 - Price Target \$5 Update - Buy - April 22, 2021 - Price Target \$5 Update - Buy - April 29, 2021 - Price Target \$5 Update - Buy - May 27, 2021 - Price Target \$5 Update - Buy - June 4, 2021 - Price Target \$5 Update - Buy - July 8, 2021 - Price Target \$5 Update - Buy - August 27, 2021 - Price Target \$5 Update - Buy - December 7, 2021 - Price Target \$5 Update - Buy - December 20, 2021 - Price Target \$5 Update - Buy - January 5, 2022 - Price Target \$5 Update - Buy - January 31, 2022 - Price Target \$5 Update - Buy - March 8, 2022 - Price Target \$5 Update – Buy – March 25, 2022 – Price Target \$5 Update - Buy - May 26, 2022 - Price Target \$5 Update - Buy - June 29, 2022 - Price Target \$5 Update - Buy - July 11, 2022 - Price Target \$5 Update – Buy – August 22, 2022 – Price Target \$5 Update - Buy - August 23, 2022 - Price Target \$5 Update - Buy - September 1, 2022 - Price Target \$5 Update - Buy - September 12, 2022 - Price Target \$5 Update - Buy - September 21, 2022 - Price Target \$5 Update - Buy - October 14, 2022 - Price Target \$5 Update - Buy - October 25, 2022 - Price Target \$5 Update - Buy - November 29, 2022 - Price Target \$5 Price Target Change - Buy - December 12, 2022 - Price Target \$8 Update - Buy - December 28, 2022 - Price Target \$8 Rating Change - Buy to Neutral - January 3, 2023 - Price Target NA Update - Neutral - January 12, 2023 - Price Target NA Update - Neutral - March 14, 2023 - Price Target NA Update - Neutral - April 10, 2023 - Price Target NA Rating Change - Neutral to Buy - May 1, 2023 - Price Target \$6.0 Update - Buy - May 30, 2023 - Price Target \$6.0 Update – Buy – June 1, 2023 – Price Target \$6.0 Update - Buy - June 15, 2023 - Price Target \$6.0 Update - Buy - June 29, 2023 - Price Target \$6.0 Update - Buy - July 18, 2023 - Price Target \$6.0

Dawson James Securities, Inc. (the "Firm") is a member of the Financial Industry Regulatory Authority ("FINRA") and the Securities Investor Protection Corporation ("SIPC").

The Firm does not make a market in the securities of the subject Company (s). The Firm has NOT engaged in investment banking relationships with CANF in the prior twelve months, as a manager or co-manager of a public offering and has NOT received compensation resulting from those relationships. The Firm may seek compensation for investment banking services in the future from the subject Company (s). The Firm has not received other compensation from the subject Company (s) in the last 12 months for services unrelated to managing or co-managing of a public offering.

Neither the research analyst(s) whose name appears on this report nor any member of his (their) household is an officer, director or advisory board member of these companies. The Firm and/or its directors and employees may own securities of the Company (s) in this report and may increase or decrease holdings in the future. As of June 22, 2023, the Firm as a whole did not beneficially own 1% or more of any class of common equity securities of the subject company(s) of this report. The Firm, its officers, directors, analysts or employees may affect transactions in and have long or short positions in the securities (or options or warrants related to those securities) of the Company (s) subject to this report. The Firm may affect transactions as principal or agent in those securities.

Analysts receive no direct compensation in connection with the Firm's investment banking business. All Firm employees, including the analyst(s) responsible for preparing this report, may be eligible to receive non-product or service-specific monetary bonus compensation that is based upon various factors, including total revenues of the Firm and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.

Can-Fite Page 4 of 5



Although the statements in this report have been obtained from and are based upon recognized statistical services, issuer reports or communications, or other sources that the Firm believes to be reliable, we cannot guarantee their accuracy. All opinions and estimates included in this report constitute the analyst's judgment as of the date of this report and are subject to change without notice.

Information about risks can be found in the "RISK ANALYSIS" section of this report.

The securities of the Company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. This report is offered for informational purposes only and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. Additional information is available upon request.

Rating Definitions:

- 1) **Buy**: the analyst believes the price of the stock will appreciate and produce a total return of at least 20% over the next 12-18 months;
- 2) **Neutral**: the analyst believes the price of the stock is fairly valued for the next 12-18 months;
- 3) **Sell**: the analyst believes the price of the stock will decline by at least 20% over the next 12-18 months and should be sold.

The following chart reflects the range of current research report ratings for all companies followed by the analysts of the Firm. The chart also reflects the research report ratings relating to those companies for which the Firm has performed investment banking services.

	Company Coverage	Investment Banking		
	Coverage		Daliking	% of
Ratings Distribution	# of Companies	% of Total	# of Companies	Totals
Market Outperform (Buy)	25	69%	2	5.50%
Market Perform (Neutral)	11	31%	2	5.50%
Market Underperform (Sell)	0	0%	0	0.00%
Total	36	100%	4	11.00%

Current as of 17-Jul-23

Analyst Certification:

The analyst(s) whose name appears on this research report certifies that 1) all of the views expressed in this report accurately reflect his (their) personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst in this research report; and 3) all Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.